Clinical trial
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell…
NCT00328198 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00328198 |
|---|---|
| Title | Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia |
| Official title | A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-Cell Chronic Lymphocytic Leukemia (B-CLL) |
| Intervention type | Biological |
| Interventions | Alemtuzumab |
| Enrollment | 86 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | May 19, 2006 |
| Last update posted | Mar 13, 2014 |
| Countries | Belgium, Czechia, France, Serbia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: